Cimzia benefits hard-to-treat CD patients

New data from the WELCOME study presented by Belgian drugmaker UCB at the Digestive Disease Week meeting demonstrate that Cimzia (certolizumab  pegol) provides sustained symptom improvement with stable dosing up to  week 26 for adult patients suffering from moderate-to-severe Crohn's  disease who are intolerant or no longer responding to Johnson &  Johnson's Remicade (infliximab).

"These are important findings, as Cimzia shows an extended duration of  response in an induction and maintenance clinical trial of Crohn's  disease patients who have failed infliximab," said study investigator  Douglas Wolf. The trial shows that Cimzia is effective up to 26 weeks in  this difficult-to-treat patient population, he added.